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Abstract 
Phenylketonuria (PKU) is a rare metabolic 
disorder comprising a number of different enzyme 
deficiencies. In Malta, dihydropteridine reductase 
(DHPR) deficiency appears to be more common than 
phenylalanine hydroxylase deficiency (classical 
PKU), and is associated with greater and long term 
neurodisability. The absence of newborn screening 
for PKU in Malta results in a later diagnosis and, to-
date, all affected patients require medical support for 
one or several problems including developmental 
delay, behavioural issues, cognitive impairment, 
epilepsy and neurodisability. These are compounded 
by problems in providing and adhering to strict low-
phenylalanine diets and, in those with DHPR, the 
regular provision of neurotransmitter and cofactor 
supplementation. As a result, although a small 
cohort, these patients create a disproportionate 
demand on health services and, in most cases, will 
continue to require long term support at all levels 
since most will be unable to lead an independent 
existence. A radical and comprehensive overhaul of 
the local care provided to children with rare 
metabolic diseases is required at all levels, starting 
with the introduction of newborn screening, 
followed by effective dietary and pharmaceutical 
provision throughout childhood and through to later 
life. 
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Introduction 
In Malta, during the period 1996-2015, five 
paediatric cases from three families with the same 
form of tetrahydrobiopterin (BH4) disorder, namely 
dihydropteridine reductase (DHPR) deficiency and 
just one child with classical PKU due to 
phenylalanine hydroxylase (PAH) deficiency have 
been diagnosed. Out of a childhood population of 
about 90,0001, the prevalence of PKU is therefore 
approximately 5.5 x 105. The carrier rate of DHPR 
deficiency in the Maltese population reported by 
Farrugia et al (2002) is high at 3.3%.2 In comparison, 
the carrier rate of PAH deficiency is 2% in northern 
Europe, 3.8% in Turkey and 3% in Ireland, but is 
unknown in Malta.2 
Case Summaries 
Case 1: PAH deficiency (Classical PKU) 
A 3 year 8 month old girl was born prematurely 
at 34 weeks gestation with respiratory distress and 
birth weight on the 50th centile. She was lost to 
neonatal follow-up and presented at 23 months of 
age with feeding difficulties, developmental delay 
and failure to thrive in the context of gross neglect 
and social problems. She was taken into care and 
fostered. As well as failure to thrive, she was noted 
to have microcephaly, fair hair and blue eyes. A 
phenylalanine (Phe) level was documented at 
120umol/L with a tyrosine level (Tyr) of 38umol/L 
(normal Phe values: 6 – 50umol/L <1 year and 10 – 
30umol/L >1 year. Table 1). 
The DHPR gene was normal and sepiapterin 
reductase was negative. She was started on a low 
phenylalanine diet with Anamix Child at 23 months 
of age with a marked improvement in terms of 
developmental progress and brisk darkening of her 
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hair. Nevertheless, mild hypotonia persisted and an 
MR of the brain showed leukomalacia. CSF 
neurotransmitters were not tested. To-date, she has 
no signs of epilepsy but remains developmentally 
delayed and attends school with the help of a learning 
school assistant (LSA) on a 1:1 basis (Table  2).  
Table 1: Normal Phenylalanine and Tyrosine levels at 0 – 31 days of life on protein containing feeds 
Phenylalanine 40 – 120 umol/L normal 
120 – 600 umol/L hyperphenylalaninaemia 
600 – 1200 umol/L mild PKU 
>1200 umol/L classical PKU
Tyrosine 55 – 147 umol/L normal 
Phe : Tyr ratio >3 is abnormal
Table 2: Summary of patient details 
*Siblings of case 4 diagnosed on newborn testing
Case Age at 
diagnosis 
Disorder Phe level 
diagnosis 
PKU 
phenotype 
Microcephaly Motor 
disorder 
Develop 
delay 
Behavioural 
problems 
Seizures 
1 23mo PAH 1693 yes yes + + + - 
4 8mo DHPR 906 yes yes ++ +++ ++ +++ 
2 5mo DHPR 700 no yes ++ ++ ++ + 
3 5mo DHPR 550 yes no + ++ ++ - 
5* newborn DHPR - no no + + + - 
6* newborn DHPR - no no - + _ - 
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Case 2: DHPR deficiency (atypical PKU) 
A 17 year old young man was born at 40 weeks 
gestation after a normal pregnancy. His birth weight 
was 2.7 kg (3rd percentile) and head circumference 
33cms (5th percentile). Apgar scores were 8 and 9 at 
1 and 5 minutes, respectively. Apart from some light 
meconium staining of the liquor, there were no other 
concerns until two months of age when he presented 
with seizures. These were initially not controlled 
with sodium valproate, and he required additional 
anticonvulsants with good effect. He did not have the 
typical ‘fair hair, blue eyes’ PKU phenotype, but 
developed hypotonia, global developmental delay 
and microcephaly. Amino acid analysis was carried 
at 5 months of age as part of the investigation for 
developmental delay, and confirmed a Phe level in 
excess of 700umol/L. 
The DHPR level was low and genetics 
subsequently confirmed the mutation consistent with 
DHPR deficiency. He was started on a low 
phenylalanine PKU diet at 5 months of age with 8 
daily exchanges, low protein diet and 4 daily PKU 
coolers. There was a slow response in terms of 
seizure control, and his developmental delay 
persisted with significant behavioural difficulties.  
CSF neurotransmitter levels were checked regularly: 
homovanillic acid (HVA) and 5-hydroxyindole-
acetic acid (5HIAA) levels were low, initially with 
reversed ratios. He required high doses of 
neurotransmitter precursors including L-3,4-
dihydroxyphenylalanine (L-DOPA), 5-
hydroxytryptophan (5HT) and folinic acid. Periodic 
episodes when his medication was not available or 
out of stock, rapidly resulted in increased 
symptomatology particularly with increased 
dystonic movements, behavioural changes and 
aggression generally over the subsequent 24-36 
hours from not receiving medication.  
This patient walked at 21 months, continued to 
progress and ran clumsily with feet apart. He uttered 
a few short sentences at 5 – 6 years of age and was 
able to fasten a few buttons at 8 years of age. 
Oculogyric crises were seen early on, with hand 
tremors lasting a few seconds and transient dystonia. 
The latter responded to clonazepam, whilst seizures 
responded partially to sodium valproate. No clear 
pyramidal or extrapyramidal motor signs were 
found. At 5 years of age, he was functioning at 
around the 3½ year level, with additional hyperactive 
and aggressive tendencies (Table 2). Brain imaging 
showed no specific abnormality.  
He has been very sensitive to treatment changes. 
Phe levels have remained moderately high, 
averaging 210 – 390umol/L, with peaks up to 472 
(2005) and between 500 – 600umol/L (2007) during 
periods of poor health and/or poor compliance. He 
has required a 1:1 LSA support at all times at school. 
He is currently employed under a ‘protected’ work 
placement attaching labels to products on a part-time 
basis. He is able to prepare simple meals and catch 
the bus home, but requires help with more complex 
tasks and will have difficulty leading a fully 
independent existence. 
Case 3: DHPR deficiency (atypical PKU) 
A 15 year old was born after a normal pregnancy 
and vaginal delivery at 40 weeks gestation. Apgar 
scores were 8 and 9 at 1 and 5 minutes, respectively. 
Birth weight was 3.55 kg (50th percentile) and head 
circumference 35cms (45th percentile). He was well 
until 5 months of age when he presented with motor 
delay, hypertonia and typical PKU phenotype with 
fair hair and blue eyes. The first Phe level at 5 
months of age confirmed a Phe level of 550umol/L 
with a tyrosine level of 75umol/L.  
The DHPR level was low and genetics 
subsequently confirmed DHPR deficiency. Initial 
CSF neurotransmitters including homovanillic acid 
(HVA), 5-hydroxyindole-acetic acid (5HIAA) and 
methyltetrahydrofolate (MTHF) were normal. He 
was started on a PKU diet with significantly reduced 
phenylalanine content at 5 months of age, initially 
via highly modified milk (Lofenalac), plus 
Aminogram, Aminex rusks, Duocal, PKU gel, 
permitted but controlled Phe-containing protein 
exchanges and PKU coolers. There was an 
improvement in terms of hypertonia, and moderate 
developmental progress was seen. He developed a 
transient dermatitis as a result of being on Lofenalac 
without any natural protein, and subsequently low 
Phe levels. This responded well to alterations in the 
Phe exchanges and his skin pigmentation improved.  
Despite normal CSF neurotransmitter levels, 
this child also required regular L-Dopa with 5- 
hydroxytryptophan (5-HT) and folinic acid 
supplementation on a 4-times and daily basis, 
respectively. During periods when his medication 
was not available, he rapidly developed increased 
dystonic movements and behavioural changes over 
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the subsequent 24hrs from not receiving medication. 
Unfortunately, these episodes have been a relatively 
frequent event, especially since his medication is 
highly specialised, only procured for a very small 
number of patients locally and not readily available 
from many sources. Numerous attempts to guarantee 
continuous supply and availability of all medications 
and specialized dietary products for PKU with the 
local pharmacy service have met with varying 
degrees of success and, despite strenuous and 
repeated efforts, intermittent non-availability 
remains an ongoing problem for all patients with 
PKU. 
Developmentally, he walked at 21 months of 
age, and ran soon afterwards. There have been 
significant behavioural difficulties, mainly in the 
form of aggression, attention deficit hyperactivity 
disorder and mood disturbance. He had several 
oculogyric crises. His head circumference remained 
normal, but he developed a mild motor disorder with 
mild hypertonia and brisk tendon reflexes. More 
recently, he has also developed dystonic movements 
and equinus gait disturbance. Neuro-imaging 
showed no specific abnormality. He has required a 
1:1 LSA support at all times at school and now 
attends a special school for children/adolescents with 
significant neurodevelopmental problems (Table 2). 
He will require a sheltered and protected work 
placement and will be unable to lead an independent 
existence without significant, long term support. 
Cases 4, 5 and 6: Siblings with DHPR deficiency 
(atypical PKU) 
Case 4: An 18 year old young man was born at 
38 weeks gestation by precipitate vaginal delivery. 
His birth weight was 2.9 kg (5th percentile) and head 
circumference 34cm (15th centile). His Apgar scores 
were 6 and 7 at 1 and 5 minutes, respectively and, 
apart from mild respiratory distress and 
hyperbilirubinaemia, was well till around 6 months 
of age when concerns arose relating to motor delay, 
reduced head growth from 50th centile to the 10th 
percentile and central hypotonia. He had a classical 
PKU phenotype and was subsequently diagnosed 
with DHPR deficiency at 9 months of age. An initial 
Phe level was 906umol/L, Tyr was 51umol/L, DHPR 
activity was low and biopterin level was high. The 
first CSF neurotransmitter levels showed an HVA of 
85 (154 – 867umol/L); HIAA 43 (89 – 367umol/L), 
and folate 16.4nmol/L (normative values at ages 0-5 
years: 13 nmol/L and  >6 years: 10 nmol/L). 
He was started on a low Phe diet at 7 months of 
age with Lofenalac with added aminogram, protein 
exchanges, aminoacid supplements, Serevit vitamins 
and mineral supplements. His response to diet in 
terms of decreasing Phe levels was very slow, and 
Phe levels persisted around 200umol/L. This was 
thought to be related to a lack of compliance with his 
diet. He was started on L-Dopa, 5- tryptophan and 
folinic acid. 
At 4years 8months he was functioning at the 2.5 
- 3 year level, and at 6 years he could count up to 50
and carry out simple addition and subtractions. He
developed a significant dystonic four limb motor
disorder with spasticity and facial tics, and frequent
adjustments of medication were carried out. Neuro-
imaging showed white matter changes in both
occipital and temporal lobes extending to the
periventricular, parietal and posterior frontal white
matter. At 5 years of age, he developed absence
seizures with bilateral continuous occipital
discharges that were resistant to treatment. This
evolved and included drop attacks that occurred
several times a day, and required various
combinations of anti-epileptic medications including
lamotrigine, topiramate, clobazam and
levetiracetam. Due to the dietary restrictions
imposed by the PKU diet itself, a ketogenic diet was
not possible at the time. A trial of steroids was also
very difficult and not tolerated. He was referred for
further assessment of his refractory epilepsy to
Guy’s Hospital in London where a vagal nerve
stimulator (VNS) was implanted. This reduced his
seizure frequency by approximately 50% but
required frequent adjustments and, in one year alone,
he travelled to London 11 times for treatment. The
family struggled with this child’s medical condition
and other practical medical problems, and emigrated
to the UK.
This patient has remained with significant 
learning difficulties and neurodevelopmental delay 
(Table 2). He will require a sheltered and protected 
work placement and will be unable to lead an 
independent existence without significant, long term 
support. 
Case 5: A younger brother of case 4, now aged 
13 years, was diagnosed with DHPR deficiency by 
genetic testing shortly after birth. Unlike his brother, 
he did not have a classical PKU phenotype. 
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Nevertheless, his first Phe level was also elevated 
and CSF neurotransmitters showed:  HVA 222 
nmol/L; HIAA223 nmol/L, and folate 19.9 nmol/L. 
He was started on a low Phe diet at 2 weeks of age 
with Minaphlex, a special formula with a linoleic:α-
linolenic acid ratio of 4:1, and was used to correct 
fatty acid imbalance associated with a PKU diet. 
Like his older brother, there was a very slow 
response in lowering Phe levels.  
Despite the early diagnosis and treatment, this 
boy also manifested developmental delay, albeit 
milder when compared to his older brother. At 4 
years of age he managed 5 to 6 word sentences, 
developed an early motor disorder with paucity of 
spontaneous movements, hypertonia and lead pipe 
rigidity reminiscent of symptomatic Parkinsonism. 
Neuro-imaging showed persistent prominence of the 
terminal myelination zone, but there were no definite 
white matter abnormalities.   
He was managed with L-Dopa, 5-HT and folinic 
acid. At 4 years of age he developed significant 
behavioural disturbances, frequent falls, attention 
deficit and frequent temper outbursts during 
mealtimes. He was very fussy in his choice of food, 
making day to day management very difficult when 
considering the reduced choice of food available to 
him. This behavioural profile was very similar to that 
of his brother but improved in tandem with his 
improved epilepsy control.    
Significant learning difficulties and 
neurodevelopmental delay necessitated a full time 
LSA in mainstream school (Table 2) and, as an adult, 
he will require sheltered and protected work 
placement and will also be unable to lead an 
independent existence without significant, long term 
support. 
Case 6: The youngest brother of cases 4 and 5 
was born and diagnosed in the UK after the family 
emigrated and clinical details of his condition are 
limited. He does, however, also have DHPR 
deficiency and manifests moderate global delay 
despite immediate diagnosis and initiation of therapy 
and a specialized diet shortly after birth. He remains 
on regular medication and a restricted diet as per his 
siblings. He has an LSA on a 1:1 basis at school and 
is likely to require long term support, even into 
adulthood (Table 2). This patient and his brothers are 
currently under the care and follow up of colleagues 
in the UK where they are now resident. 
Discussion 
Medical impact on patients and families 
Dietary intervention 
The goal of PKU treatment is to maintain plasma 
phenylalanine (Phe) levels with a ‘normal’ range that 
supports growth, development and mental function 
while providing a nutritionally complete diet. Phe is 
an essential amino acid and required for protein 
synthesis, therefore very low levels are also 
detrimental. Individuals with 
hyperphenylalaninaemia require a low Phe diet that 
is based on two interrelated dietary modifications to 
achieve metabolic control of plasma Phe levels. 
Natural foods are severely restricted to limit protein 
intake while providing adequate amounts of Phe. 
This involves elimination of all sources of animal 
protein, legumes and nuts, as well as limiting 
amounts of bread, pasta, rice and some vegetables. 
Low protein bread and pasta products made from 
starch are used to provide energy.  
Consumption of an amino-acid based, Phe-free 
formula milk or amino-acid medical food is required 
to provide adequate protein, vitamins, minerals and 
energy due to their restriction in natural foods. The 
UK Medical Research Council Working Party on 
PKU recommends a total protein intake of 3g/kg/day 
for children under 2 years of age and 2g/kg/day for 
children over 2 years of age. These amounts exceed 
recommendations for protein intake in the non-PKU 
population by 30%. A typical low phe diet is based 
on a system of exchanges. In the UK system, one 
‘exchange’ amounts to 50mg Phe which is 
approximately 1g protein. Unfortunately, this 
assumption does not work for protein from fruit and 
vegetables, the content of which are calculated using 
special databases.3 
Medication 
In children with atypical PKU, CSF amino acids 
and neurotransmitter imbalance is common and need 
to be managed. This requires periodic lumbar 
punctures and daily supplementation with folinic 
acid, tryptophan and L-Dopa. Epilepsy and 
behaviour disturbance are frequent problems in this 
group of children and need to be managed 
appropriately with anticonvulsants, behavioural 
therapy and, if necessary, sedative medication.  
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Psycho-social and educational impact 
A study by Di Ciommo et al 4 focused on the 
lived experience of patients with PKU. This was a 
phenomenological study of 20 patients using a 
validated semi-structured interview in an Italian 
tertiary level metabolic centre. They looked at the 
personal experiences of these patients through (a) 
their knowledge and conceptualization of PKU, (b) 
their perception of being different and (c) their 
adherence to diet. It was shown that children and 
young adults with early treated PKU had a fair 
knowledge of their condition but did not feel that 
they were truly ill.4 Although they perceived no 
direct, immediate, adverse effects of their disease, 
they adhered to their diet. They reported a difference 
between themselves and their peers. The fear of 
stigmatization tended to prevent them from 
participating in social occasions during which food 
was shared. One coping strategy reported by these 
individuals to overcome isolation was to disclose 
their condition to their peers. 
From the cognitive point of view, early 
diagnosis and treatment of PKU can prevent the 
severe neurocognitive consequences of this disorder. 
However, even early- and well-treated patients 
experience hidden disabilities, including subtle 
deficits in executive functioning, mild reductions in 
mental processing speed, social difficulties, and 
emotional problems that may remain unnoticed for 
years. 
PKU has been shown to be associated with poor 
executive function that may impact treatment 
adherence and may lead to psychosocial deficits 
including difficulty in forming interpersonal 
relationships, achieving autonomy, attaining 
educational goals, and having healthy emotional 
development. A degree of depressive and anxiety 
symptoms may also be present. The combination of 
cognitive and psychiatric disturbances acts as a 
hidden disability.5 Patients with atypical and BH4 
disorders are more likely to be adversely affected 
with a greater incidence and degree of 
neurodisability.6 From the parental point of view, 
mothers of children with biochemical genetic 
disorders report greater stress and worry, less 
satisfaction with social support, greater difficulty 
meeting their child's extra care needs, and more 
impact on multiple aspects of their personal lives.7 
Financial impact 
A review of the cost of special dietary needs in 
10 PKU specialist centres, reported that the mean 
annual cost of protein substitutes across 4 age groups 
(2, 8, 15 years and adults) ranged from €4,273 to 
€21,590 per patient. The cost of low-protein products 
also differed; the mean cost of low-protein bread 
varied from €0.04 to €1.60 per 100kcal. All protein 
substitutes were either fully reimbursed or covered 
by health insurance. However, reimbursement for 
low-protein products varied and state benefits 
differed between centres.8 
In a cross-sectional study about time 
consumption and cost of PKU in the Netherlands, it 
was shown that the median out-of-pocket cost per 
patient was shown to be €604 annually (in all age 
groups)9. These costs were mainly due to 
expenditure on low-protein food products and for a 
small part on costs related to PKU testing equipment, 
postage of Phe blood tests, taking extra luggage on 
holiday to accommodate PKU equipment and 
attending PKU events. This study assessed whether 
these additional PKU-related costs are offset by the 
potentially cheaper natural diet imposed upon PKU 
patients that contains very little or no regular bread, 
dairy products or meat. In comparison to the general 
population, a Dutch adult on a normal diet will spend 
a mean amount of €1,200 annually on meat, cheese, 
milk, yoghurt and bread. For patients with PKU this 
expenditure is replaced by the costs of the low 
protein products. It may be expected that costs 
between protein containing and low protein food 
products will balance out in patients depending on 
disease severity and the need for low protein food 
products. Taking this into account, the authors 
concluded that it is unlikely that there will be a large 
burden of extra out-of-pocket cost for families of 
patients with PKU.9 
It must be stressed, however, that the costs of the 
Phe free protein supplements in a mixture with 
vitamins and minerals, which are an essential part of 
the diet of patients with PKU, vary per country but 
may be as high as €30,000 annually. In most 
European countries these costs are reimbursed by the 
government, or as is the case in the Netherlands, by 
health insurance. To guarantee proper dietary 
treatment and compliance of patients with PKU and 
to avoid a disproportionate financial burden for 
patients and families, it is essential that costs of the 
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Phe free protein supplements are reimbursed in all 
countries.9 
Impact on Health services 
According to the National Institutes of Health 
Consensus Development Conference Statement 
about the management of phenylketonuria, health 
systems need to respond effectively in order to 
ensure metabolic control across the lifespan of 
individuals with PKU. Comprehensive, 
multidisciplinary, and integrated systems are needed 
to deliver this type of care to individuals with PKU. 
Consistent and coordinated screening, treatment, 
data collection, and patient support programs are 
necessary. Moreover, there should be equal access to 
culturally sensitive, age-appropriate treatment 
programs. They also state that uniform policies must 
be established to remove financial barriers to the 
acquisition of medical foods and modified low-
protein foods and to provide access to support 
services needed to maintain metabolic control in 
individuals with PKU.10 In practical terms, the above 
requirements are best met by a coordinated, expert 
team.11 
Current challenges in management of PKU in 
Malta 
Late diagnosis 
The absence of neonatal screening in Malta is a 
major drawback that mitigates against early 
treatment. This is further compounded by the fact 
that, in Malta, atypical PKU appears to be more 
common than classical PKU where the prognosis is 
perhaps more heavily dependent on careful and early 
treatment. Given the absence of newborn screening 
in Malta, over the past 18 years, 4 children with PKU 
were diagnosed after the age of 5 months and, in 
some cases, much later in childhood, as shown in 
Table 1. Two siblings of the index case were 
screened immediately and diagnosed shortly after 
birth. 
Paediatricians need to keep the possibility of 
PKU always in mind in those children with 
unexplained developmental delay, abnormalities in 
tone, movement disorders, or atypical cerebral palsy. 
Despite current literature stating that the use of 
‘metabolic screens’ in the investigation of children 
with global developmental delay tends to have a low 
positive yield, this may be an argument in favour of 
performing a metabolic screen in such situations. 
Furthermore, since PKU is a rare disease, medical 
practitioners will find it difficult to acquire enough 
experience to identify clinical signs suggestive of 
PKU early enough. This effectively strengthens the 
case for neonatal screening.  
Shared care 
PKU is best managed in a tertiary metabolic 
centre, and this type of management has been shown 
to be more effective in PKU when compared to 
management by general paediatric centres.5 Outside 
of these Centres, the level of experience in dealing 
with PKU is very limited. This scenario applies to 
Malta, whereby patient care is shared with a tertiary 
specialist centre in London. Phe levels need to be 
checked as often as needed/frequently, and 
communicated with the specialist team. Delays in the 
availability of results may not allow for appropriate 
titration of doses and changes in diet. Furthermore, 
CSF neurotransmitter levels may not be assayed 
often enough according to recommendations because 
of logistical problems with sampling and non-
availability of laboratory assays at a local level. 
Indeed, CSF amine levels are obtained in London 
and necessitate an annual visit overseas. Despite this, 
local follow-up remains an important part of long 
term management with families still seeking advice 
about common problems in PKU such as doses of L-
Dopa, 5-HT, seizure control and management of 
movement disorders.  
Dietary supplies 
The lack of specialist dietetic support is another 
important local drawback. This is regularly 
associated with and compounded by frustrating 
difficulties in procuring certain special food items, 
ensuring adequate stocks and avoiding ‘out of date’ 
issues, making provision and compliance with a low 
Phe diet very difficult. It would also seem that in 
contrast to other conditions requiring special dietary 
and/ or nutritional support, families of children with 
PKU struggle in order to secure timely delivery of 
the required special dietary items. These children 
only consume small amounts of specific food items 
that change from time to time, and are not widely 
available, thereby discouraging local pharmaceutical 
agents to stock these items.  
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Conclusion 
National screening 
PKU is a chronic condition with significant 
morbidity for affected patients and a burden on 
health care costs. It fulfils all criteria for newborn 
screening and is sufficiently prevalent in the local 
population such that an official report strongly 
recommended it’s addition to the current National 
Programme in 2005.12 There is no medical reason 
why neonatal screening should not be introduced in 
Malta in line with current international 
recommendations.13 Once introduced, infants who 
are found to have high phenylalanine levels will be 
recalled urgently to (a) confirm high Phe levels, and 
(b) depending on the level, plan further investigation,
(c) liaise with tertiary centre and start a low Phe diet.
It is important to keep in mind that failure to pick up
PKU early on and any delay in starting effective
treatment may carry medico-legal implications.
Central pooling of supplies 
Although there are only very few children who 
require low Phe food products, they should receive 
the required products at the right quantity and at the 
right time. This is an important issue that has ethical 
as well as potentially serious medico-legal 
implications.   
It is therefore time to push for appropriate 
changes in pharmacy service that effectively respond 
to the nutritional requirements of these children in 
real time. It may be possible to introduce a system 
whereby these families are given access to carefully-
monitored credit that can be used to order and 
purchase their special foodstuffs directly from their 
tertiary centre. At this day and age, this is technically 
very feasible and convenient for all. It may also be 
more cost-effective as it eliminates expired / unused 
/ surplus items.  
Shared care 
PKU, like other rare disease, needs to be 
managed under the direction of a specialist centre. 
Nonetheless, appropriate and effective joint care 
needs to be maintained between the local team and 
the tertiary team, and should incorporate dietetic 
input. 
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